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Abstract 
De novo gene birth from non-genic DNA has been recently reported as one of the models of new 
gene generation. However, the mechanisms by which de novo evolved proteins modify pre-existing 
gene regulatory networks to modulate cellular phenotypes remain unknown. We previously showed 
that NCYM, a MYCN cis-antisense gene, encodes a de novo evolved protein in the taxonomically 
restricted group including humans. NCYM is co-amplified with the MYCN gene in primary human 
neuroblastomas, and the gene product promotes aggressiveness of neuroblastoma via stabilization of 
MYCN. In this study, we show that NCYM forms a positive feedback loop with OCT4, a core 
regulatory gene maintaining a multipotent state of neural stem cells. In 36 MYCN-amplified primary 
human neuroblastomas, OCT4 mRNA expression was associated with unfavorable prognosis and 
was correlated with that of NCYM. OCT4 induced both NCYM and MYCN in human neuroblastoma 
cells whereas NCYM stabilized MYCN to induce OCT4 and stem cell-related genes, including 
NANOG, SOX2, and LIN28. In sharp contrast to MYCN, enforced expression of c-MYC did not 
enhance OCT4 expression in human neuroblastoma cells. All-trans retinoic acid (ATRA) treatment 
reduced MYCN, NCYM, and OCT4 expression, accompanied by the decreased amount of OCT4 
recruited onto intron 1 region of MYCN. Knockdown of NCYM or OCT4 inhibited neurosphere 
formation and promoted asymmetric cell division in MYCN-amplified human neuroblastoma cells. 
These results suggest that the functional interplay between NCYM and OCT4 maintains stem 
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cell-like state of human neuroblastomas contributing to their aggressiveness and illustrate that a de 
novo evolved gene can regulate cellular phenotypes by the modulation of pre-existing gene 
regulatory networks. 
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Introduction 
Neuroblastoma is a pediatric solid tumor that arises in sympatho-adrenal tissues (1). 
Amplification of the MYCN oncogene is frequently observed in unfavorable 
neuroblastomas (2), and aberrant expression of MYCN contributes to neuroblastoma 
progression (3). MYCN is a transcription factor that regulates a wide variety of 
biological phenomena, including cell-cycle progression, apoptosis, differentiation and 
stemness (4, 5). MYCN transgenic mice spontaneously develop neuroblastomas (3), but 
unlike human MYCN-amplified neuroblastomas, the mice rarely have metastatic 
tumors. Recently, we reported that NCYM, a MYCN cis-antisense gene, encodes a 
protein that functions as an onco-promoting factor (6). The coding sequence of NCYM is 
not evolutionally conserved in mice, and the NCYM gene is co-amplified with MYCN in 
human primary neuroblastomas (6). MYCN directly targets NCYM for transcriptional 
activation whereas NCYM stabilizes MYCN protein, forming a positive auto-regulatory 
loop (6, 7). NCYM expression caused metastatic tumors in MYCN/NCYM double 
transgenic mice and inhibited apoptotic cell death (6). However these results do not rule 
out the possibility that NCYM is involved in other cellular phenotypes to promote the 
aggressiveness of neuroblastoma. 
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Neuroblastomas originate from neural crest cells that differentiate into multiple cell 
lineages (8). Some neuroblastoma cells retain multipotency and highly express stem 
cell-related genes, such as OCT4 (9) and LIN28 (10). Intermediate (I)-type 
neuroblastoma cells highly express OCT4 and differentiate into neuroblastic (N)-type or 
substrate adherent (S)-type cells in response to retinoic acid or BrdU treatment, 
respectively (11). OCT4+/Tenascin C+ neuroblastoma cells were reported to serve as 
progenitors of tumor-derived endothelial cells, promoting neovascularization of the 
tumors (9). Furthermore, OCT4 is expressed in side-population cells of neuroblastoma 
(12). Despite these correlations between OCT4 expression and the stem cell-like state of 
neuroblastomas, the functional roles of OCT4 in neuroblastoma pathogenesis remain 
unclear. In this study, we investigated the biological and clinical significance of OCT4 in 
neuroblastomas and found that the newly evolved network between MYCN, NCYM and 
OCT4 regulates aggressiveness of human neuroblastomas.  
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Results 
High expression of OCT4 was associated with poor prognoses in MYCN-amplified 
human neuroblastomas 
To examine the prognostic significance of OCT4 mRNA expression in human 
neuroblastoma, total RNA was extracted from 36 MYCN-amplified and 67 
MYCN-non-amplified primary neuroblastomas and subjected to quantitative real-time 
RT-PCR. Kaplan–Meier analysis showed that high levels of OCT4 mRNA expression 
were significantly associated with poor outcomes in MYCN-amplified human 
neuroblastomas (Figure 1A), but not in MYCN-non-amplified human neuroblastomas 
(Figure 1B). 
 
The expression levels of OCT4 were correlated with prognostic factors 
We next checked the relationship between the expression of OCT4 and prognostic 
factors. The expression levels of OCT4 were significantly correlated with International 
Neuroblastoma Staging System (INSS) stage, Shimada pathology and expression of 
NCYM and MYCN in MYCN-amplified primary neuroblastomas (Table 1). In addition, 
univariate Cox regression analysis of 36 MYCN-amplified primary neuroblastomas 
indicated that high levels of OCT4 mRNA expression tended to correlate with poor 
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prognosis (Table S1). Multivariate Cox regression analysis also revealed that OCT4 
mRNA expression was not independent of NCYM and MYCN mRNA expression in 
MYCN-amplified primary neuroblastomas (Table S2). 
 
NCYM induced OCT4 via induction of MYCN 
We next examined the factors that predict OCT4 expression in primary neuroblastomas 
by multiple regression analysis (Table S3). The expression levels of NCYM, NANOG, 
KLF4, and c-MYC and MYCN amplification significantly contributed to the prediction 
of OCT4 expression in primary neuroblastomas (Table S3). Furthermore, the expression 
levels of NCYM mRNA were positively correlated with those of OCT4 and NANOG, 
whereas KLF4 expression was inversely correlated with that of MYCN and NCYM 
(Table S4). 
 
These results prompted us to assess whether NCYM regulates OCT4 as well as stem 
cell-related genes in human neuroblastoma cells. Overexpression of NCYM or MYCN, 
but not c-MYC, induced OCT4 mRNA expression (Figure S1 and S2) as well as NANOG, 
LIN28 and SOX2, whereas NCYM or MYCN did not enhance c-MYC or KLF4 (Figure 
S1). Knockdown of NCYM decreased OCT4 and MYCN expression at both mRNA and 
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protein levels (Figure 2A and B), and suppressed their promoter activities (Figure 2C). A 
previous report suggested that MYCN is directly recruited onto the distal enhancer of 
human OCT4 (14). We thus checked the recruitment of MYCN onto putative E-box sites 
found in human OCT4 enhancer regions (Figure 2D). Endogenous MYCN protein was 
recruited onto the distal enhancer region (Figure 2D and E, #1), but not in the proximal 
enhancer region (Figure 2D and E, #2). NCYM knockdown diminished MYCN binding 
to the distal enhancer of OCT4 (Figure 2E). Together these results suggest that NCYM 
regulates OCT4 transcription via induction of MYCN. 
 
In sharp contrast to human neuroblastoma cells, overexpression of NCYM in mice did 
not induce stem cell-related genes both in vitro (Figure S3) and in vivo (Figure S4). 
Furthermore, the E-box at the distal enhancer region of OCT4 is not evolutionally 
conserved among species (Figure S5A). 
 
OCT4 directly stimulated MYCN transcription in human neuroblastoma 
OCT4, SOX2 and NANOG form core networks in embryonic stem (ES) cells by their 
mutual transcriptional regulations (15). We thus examined whether OCT4 regulates 
MYCN/NCYM transcription in human neuroblastoma cells. In BE (2)-C 
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MYCN-amplified neuroblastoma cells, shRNA-mediated knockdown of OCT4 
downregulated NCYM and MYCN at both the mRNA and protein levels (Figure 3A and 
B). Overexpression of OCT4 induced the expression and promoter activities of MYCN 
and NCYM in SK-N-AS MYCN-non-amplified neuroblastoma cells (Figure S6). In BE 
(2)-C cells, OCT4 knockdown suppressed the promoter activities of OCT4 and MYCN, 
whereas it did not affect NCYM promoter activity (Figure 3C). These results suggest 
that OCT4 may not directly affect NCYM transcription at the endogenous expression 
levels. Overexpression of OCT4 enhanced activities of MYCN reporter constructs 
containing the intron 1 region of MYCN (Figure 3D). We found two putative OCT4 
binding sites within the intron 1 region, and generated luciferase reporter constructs 
harboring mutations in the OCT4 binding sites (Figure 3E). Mutations in the upstream 
OCT4 binding sequence diminished OCT4-mediated enhancement of MYCN promoter 
activity, whereas MYCN promoter constructs containing the wild-type upstream OCT4 
site sustained the response to OCT4 overexpression (Figure 3E). Chromatin 
immunoprecipitation (ChIP) assay showed that OCT4 was directly recruited onto the 
intron 1 region of MYCN (Figure 3F and G, #3). We also observed the recruitment of 
OCT4 to the promoter of MYCN (Figure 3F and G, #2), although the OCT4 site in the 
MYCN promoter was not responsible for OCT4-mediated enhancement of MYCN 
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promoter activity (Figure 3E). We next checked the conservation of the OCT4 binding 
site within intron 1 among species, and found that it is mostly conserved among 
primates, but not in mice (Figure S5B). 
 
OCT4 is downregulated upon differentiation of neuroblastoma cells 
BE (2)-C I-type neuroblastoma cells are stem cell-like cells that show the ability to 
differentiate into N-type cells in response to retinoic acid treatment (11) and MYCN 
expression is downregulated during the differentiation (11). We assessed the expression 
of NCYM and OCT4 in BE (2)-C I-type cells treated with ATRA (Figure 4A and B). As 
reported previously (11), BE (2)-C I-type cells differentiated into N-type cells with 
marked neurite extensions (Figure 4C and D), accompanied by a rapid decrease of 
MYCN expression (Figure 4A and B). The decrease of MYCN was followed by the 
downregulations of NCYM, OCT4 and SOX2 (Figure 4A and B), whereas no significant 
changes were observed in the expression levels of NANOG (Figure 4A). In good 
accordance with the strong correlation in primary tumors (Table S4), NCYM and OCT4 
expressions showed similar expression patterns in ATRA-treated BE (2)-C cells (Figure 
4A and B). Furthermore, ATRA treatment decreased MYCN binding to the distal 
enhancer of OCT4 (Figure 4E) and OCT4 binding to the intron 1 region of MYCN 
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(Figure 4F). Therefore, retinoic acid-induced neuronal differentiation abrogated the 
positive auto-regulatory loops formed by MYCN, NCYM and OCT4 via the simultaneous 
downregulation of their expressions. 
  
OCT4 and NCYM maintain self-renewal of neuroblastoma cells 
We next examined whether OCT4 and NCYM contributes to self-renewal of 
neuroblastoma cells. Knockdown of NCYM or OCT4 in BE (2)-C cells inhibited 
neurosphere formation (Figure 5B and C) and cellular invasion (Figure 5D and E), 
whereas the cell proliferations were not significantly changed within 3 days after 
shRNA transduction (Figure 5A). Izumi et al. recently reported that neuroblastoma 
cells have stem cell-like characteristics showing both asymmetric and symmetric cell 
divisions (SCD) in vitro and that MYCN suppresses the ACD (16). Consistent with the 
previous report (16), immunocytochemistry analyses showed a high percentage of cells 
exhibiting ACD in SK-N-AS MYCN-non-amplified cells compared with BE (2)-C 
MYCN-amplified cells (Figure S7). shRNA-mediated knockdown of NCYM or OCT4 
significantly increased the number of cells exhibiting ACD in BE (2)-C cells (Figure 5F 
and G). Collectively, these results suggest that NCYM and OCT4 maintain self-renewal 
of human neuroblastoma cells. 
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Discussion 
Here, we found that OCT4 promotes aggressiveness of MYCN-amplified neuroblastoma 
cells by forming a positive regulatory loop with MYCN/NCYM. Despite a correlation 
between OCT4 expression and a stem cell-like state of neuroblastomas, the clinical 
significance of OCT4 in neuroblastomas has remained elusive. In this study, we found 
that OCT4 was correlated with NCYM expression and undifferentiated pathological 
characteristics in Shimada pathology. Furthermore, the expression levels of OCT4 were 
associated with unfavorable outcomes in the MYCN-amplified tumors, but not in the 
MYCN-non-amplified tumors. A previous study showed that MYCN expression was 
inversely correlated with c-MYC in neuroblastoma (17). Moreover, low expression levels 
of KLF4 mRNA were associated with poor neuroblastoma outcome (18). Our results 
showed that NCYM was also positively correlated with NANOG expression and was 
inversely correlated with KLF4 and c-MYC. In vitro experiments showed that 
overexpression of NCYM induced OCT4, SOX2 and NANOG, but not c-MYC or KLF4. 
Thus, among stem cell-related genes, NCYM mainly regulated the transcription of 
genes related to maintenance of pluripotency of ES cells (19-21) in human 
neuroblastoma cells. NCYM stabilized MYCN to stimulate OCT4 transcription whereas 
OCT4 induced NCYM and MYCN via direct transcriptional activation of MYCN. 
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Therefore, MYCN, NCYM and OCT4 cooperate to induce each other, resulting in 
keeping their own expression at high levels and maintaining self-renewal of cells in 
MYCN-amplified neuroblastomas. Differentiation-inducing therapy by retinoic acid 
treatment has improved the overall survivals of MYCN-amplified neuroblastomas (22), 
and ATRA treatment abrogated the mutual transcriptional regulations between MYCN, 
NCYM and OCT4, inducing neuroblastoma cell differentiation. Previous studies have 
shown that OCT4 positive neuroblastoma cells have resistant potency to conventional 
therapy (12) and multipotency to differentiation (9). Therefore, the disruption of 
MYCN/NCYM-OCT4 network could be a good therapeutic strategy for aggressive 
tumors. 
 
Previous reports have shown the physiological roles of OCT4 in the transcriptional 
regulation of MYC family members in various species (23). OCT4 stimulates MYC 
transcription for cell proliferation in human and mouse ES cells (24) and activates mych 
transcription for cell survival during zebrafish gastrulation (25). In the present study, 
we found the pathological significance of OCT4 for MYCN transcription in human 
neuroblastoma cells. The OCT4 binding sequence in MYCN intron 1 is not present in 
mice, but it is mostly conserved in other mammals. Although the E-box responsible for 
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MYCN-mediated MYCN/NCYM transcription is highly constrained in mammalians 
(Figure S8), NCYM coding sequences are conserved only in humans and monkeys (6). 
Therefore, the transcriptional regulation of MYCN by OCT4 and the positive 
auto-regulation of MYCN may have evolved before the emergence of the NCYM gene, 
and NCYM strengthens the MYCN-OCT4 network by stabilizing MYCN, thereby 
inducing OCT4 transcription. NCYM is positively selected during evolution (6); however, 
its physiological roles in normal stem have remained unknown. Because new genes 
have been reported to rapidly become essential after emergence (26, 27), future studies 
will need to examine the physiological roles of the MYCN/NCYM-OCT4 networks in the 
maintenance of human normal stem cells. 
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Materials and Methods 
Clinical specimens 
Tumor RNA samples were obtained from 36 MYCN-amplified and 67 MYCN-non-amplified tumor 
specimens in our Neuroblastoma Resource Bank at the Chiba Cancer Center Research Institute. The 
specimens were kindly provided from various institutions and hospitals where informed consent was 
obtained. All tumors were diagnosed clinically as well as pathologically as neuroblastoma and staged 
according to the INSS criteria. Total RNA was extracted from each frozen tissue according to the 
previous report (13). 
 
Cell culture 
The human neuroblastoma cell line SK-N-AS (MYCN-non-amplified) was maintained in RPMI 1640 
medium (Wako, Osaka, Japan) supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
(Gibco, Life Technologies, Carlsbad, CA, USA). The other human neuroblastoma cell line BE (2)-C 
(MYCN-amplified) was cultured in a 1:1 mixture of minimal essential medium (Gibco) and Ham’s 
Nutrient Mixture F-12 (Gibco) supplemented with 15% heat-inactivated FBS (Gibco) with 1% MEM 
nonessential amino acids (Gibco). Mouse neuroblastoma Neuro2a cells and HEK293T cells were 
cultivated in Dulbecco's modified Eagle's medium (Wako) supplemented with 10% heat-inactivated 
FBS (Gibco). 
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Overexpression of NCYM, OCT4, and MYCN in neuroblastoma cell lines 
We previously constructed a pcDNA3-FLAG-NCYM that expresses NCYM fused to the FLAG 
epitope at the NH2 terminus and cloned into the pcDNA3.1. (pcDNA3) vector (Promega, 
Southampton, UK) and pcDNA3-MYCN (6). The OCT4 complementary DNA was digested from 
pCR-TOPO-OCT4 (Funakoshi, Tokyo, Japan) by EcoRI and introduced into a pcDNA3 expression 
vector. The sequence of the entire OCT4 open reading frame was confirmed by sequencing. Before 
transient transfection, cells were seeded at 1 × 10
5
 cells/mL in a dish and allowed to adhere 
overnight. Transient transfection was performed using Lipofectamine 2000 transfection reagent 
(Invitrogen, Karlsruhe, Germany) according to the manufacturer’s instructions. Cells were analyzed 
48 hours after the transfection. 
 
Gene knockdown assay 
The following gene-specific shRNAs were used: NCYM sh-1 (N-cym 1 custom shRNA; Sigma, St 
Louis, MO, USA) 5′-tggcaattgcttgtcattaaa-3′, NCYM sh-2 (N-cym 2 custom shRNA; Sigma) 
5′-gaggttgctcctgtgtaatta-3′, OCT4 sh-1 (TRCN0000004879; Sigma) 
5′-ccggtcattcactaaggaaggaattctcgagaattccttccttagtgaatgattttt-3′, OCT4 sh-2 (TRCN0000004881, 
Sigma) 5′-ccggccctcacttcactgcactgtactcgagtacagtgcagtgaagtgagggttttt-3′ and control shRNA 
(Non-Target shRNA SHC002) were purchased from Sigma. The lentivirus was produced by 
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co-transfecting pCMVR and pMDG plasmids into HEK293T cells. Before the co-transfection, cells 
were seeded at 2 × 10
5
 cells/mL in a dish and allowed to adhere overnight. Co-transfection was 
performed using FuGENE HD reagent (Roche, Mannheim, Germany) according to the 
manufacturer’s instructions. At 24 and 48 hours after transfection, the viral supernatants were 
collected and mixed with culture medium. Neuroblastoma cells were cultured for 12 hours in a 1:1 
mixture of viral supernatants and culture medium. All shRNA-mediated knockdown cells were 
subjected to experiments 72 hours after infection. 
 
All-trans retinoic acid (ATRA) treatment 
ATRA was purchased from Wako and diluted to 5 mM for experimental use. ATRA was added at the 
final concentration of 5 µM 24 hours after cell seeding at 2 × 10
5
 cells/mL for each experiment. 
 
Quantitative real-time RT-PCR analysis 
Total RNA was isolated from the frozen tumor samples of transgenic mice with Isogen (Nippon 
Gene, Tokyo, Japan), and treated with RNase-free DNase I. Total RNA was prepared from primary 
neuroblastoma tissues and cell lines, followed by first-strand synthesis. Quantitative real-time 
RT-PCR was carried out using the SYBR Green and Taqman method as described by the 
manufacturer (Applied Biosystems, Foster City, CA, USA). Primer sets used are as follows: NCYM 
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(endogenous) 5′-CTAGAGCCGAGGGAATTTCTTTT-3′ and 5′-CCCAGCTTTGCAGCCTTCT-3′, 
NCYM 5′-CGCCCCCTTAGGAACAAGAC-3′ and 5′-GCGCCCCTCTTCTTTCAATT-3′, MYCN 
(endogenous) 5′-TCCATGACAGCGCTAAACGTT-3′ and 
5′-GGAACACACAAGGTGACTTCAACA-3′, MYCN 5′-CCTTCGGTCCAGCTTTCTCA-3′ and 
5′-GGCCTTCTCATTCTTTACCAACTC-3′, OCT4 (endogenous) 
5′-GGGTTTTTGGGATTAAGTTCTTCA-3′ and 5′-GCCCCCACCCTTTGTGTT-3′, OCT4 
5′-CGACCATCTGCCGCTTTG-3′ and 5′-GCCGCAGCTTACACATGTTCT-3′, NANOG 
5′-CCAAAGGCAAACAACCCACTT-3′ and 5′-CGGGACCTTGTCTTCCTTTTT-3′, SOX2 
5′-ACAGCAAATGACAGCTGCAAA-3′ and 5′-TCGGCATCGCGGTTTTT-3′, KLF4 
5′-ACCAGGCACTACCGTAAACACA-3′ and 5′-ATGCTCGGTCGCATTTTTG-3′, c-MYC 
5′-AGGGTCAAGTTGGACAGTGTCA-3′ and 5′-TGGTGCATTTTCGGTTGTTG-3′. The mRNA 
levels of genes were standardized by β-actin or GAPDH. 
 
Western blotting 
We resolved cell proteins by SDS-PAGE prior to electroblotting onto a PVDF membrane. We 
incubated the membranes with the following primary antibodies overnight: anti-NCYM (1:1000 
dilution; (6)), anti-OCT4 (1:1000 dilution; Cell Signaling Technology, Danvers, MA, USA), 
anti-MYCN (1:1000 dilution; Calbiochem, San Diego, CA, USA), and anti-actin (1:2000 dilution; 
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Sigma). The membranes were then incubated with a horseradish peroxidase-conjugated secondary 
antibody (anti-rabbit IgG at 1:2000 dilution or anti-mouse IgG at 1:2000 dilution; Cell Signaling 
Technology) and the bound proteins were visualized using a chemiluminescence-based detection kit 
(ECL and ECL pro kit; Amersham, Piscataway, NJ, USA). 
 
Chromatin immunoprecipitation (ChIP) assay 
BE (2)-C cells were infected with lentivirus of shNCYM, shOCT4, or shMYCN. ChIP assays were 
performed with a ChIP assay kit (Millipore, Temecula, CA, USA) according to the manufacturer’s 
instructions using anti-NCYM (6), anti-OCT4 (Cell Signaling Technology), anti-MYCN 
(Calbiochem), normal mouse IgG (Jackson ImmunoResearch Laboratories Inc., Suffolk, UK), or 
normal rabbit IgG (Jackson ImmunoResearch Laboratories Inc.). The primer sequences for the 
OCT4 and MYCN promoters were as follows: OCT4 promoter 1 
5′-GAGGATGGCAAGCTGAGAAA-3′ and 5′-CTCAATCCCCAGGACAGAAC-3′, OCT4 
promoter 2 5′-GTTGGGGAGCAGGAAGCA-3′ and 5′-GGGGCAGCTCTAACCCTAAA-3′, 
MYCN promoter 1 5′-GACAGCACTTCCATCTCGGTAAA-3′ and 
5′-GCCACCATTCTCCCCAGTT-3′, MYCN promoter 2 5′-GGCGCCTCCCCTGATTT-3′ and 
5′-GAGGGAGAAAGGAGAGGAAAGC-3′, MYCN promoter 3 
5′-CTGTCGTAGACAGATTGTAC-3′ and 5′-AACCAGGTTCCCCAATCTTC-3′ 
 19 
 
 
Luciferase reporter assay 
MYCN (−221/+1312), MYCN (−1030/+21), and NCYM-luc (−149/+1384) plasmids (where +1 
represents the transcription start site) were generated in previous reports (6, 7). We then subcloned 
the MYCN promoter region (−221/+465) into the pGL3-basic vector using MYCN (−221/+1312) as 
a template. MYCN promoter (−221/+409) and MYCN promoter (−221/+210) were made by 
PCR-based amplification using MYCN promoter (−221/+465) as a template. Putative OCT4 binding 
site wild-type and mutant of MYCN promoter were generated from MYCN promoter (−221/+465). 
Primer sets used were as follows: 5′-GCAGCCTTCTCTCTGCAAAG-3′ (forward) and 
5′-CCTAATCCTTTTGCAGCCC-3′ (reverse, MYCN promoter −221/+409 putative OCT4 binding 
site WT), 5′-CCTAATCCTTTTACAGCCC-3′ (reverse, MYCN promoter −221/+409 putative OCT4 
binding site MT1), 5′-CCTAATCCTTTTACTGCCC-3′ (reverse, MYCN promoter −221/+409 
putative OCT4 binding site MT2), 5′-GCAGGGCTTGCAAACCGCCC-3′ (reverse, MYCN promoter 
−221/+201 putative OCT4 binding site WT) or 5′-GCAGGGCTTGGAAAGCGCCC-3′ (reverse, 
MYCN promoter −221/+201 putative OCT4 binding site MT). Underlined sequences in the reverse 
primers indicate the wild-type or mutated OCT4 binding site. OCT4 promoter sequences containing 
the OCT4 promoter regions at nucleotides −4991 to +77 from the transcription start site were 
obtained from Addgene (Cambridge, MA, USA). shRNA-transfected BE (2)-C, SK-N-AS and 
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Neuro2a cells were seeded at 5 × 10
4
 cells/well in a 12-well plate and allowed to adhere overnight. 
SK-N-AS and Neuro2a cells were co-transfected the following day with empty vector (pcDNA3), 
pcDNA3-FLAG-NCYM, pcDNA3-OCT4, or pcDNA3-MYCN along with 400 ng of NCYM, OCT4, 
or MYCN luciferase reporter construct and 40 ng of Renilla TK with Lipofectamine 2000 
(Invitrogen). At 48 hours after the second transfection, the cells were harvested and the luciferase 
activity was determined using a dual luciferase assay system (Promega) according to the 
manufacturer’s instructions. 
 
Migration and invasion assay 
The invasive potential of neuroblastoma cells in vitro was evaluated using Matrigel-coated Transwell 
inserts (BD Biosciences, San Jose, CA, USA) according to the manufacturer’s instructions. BE (2)-C 
cells transfected with the control shRNA or NCYM sh-1 and OCT4 sh-1 were seeded onto an insert 
with 8-μm pores (BD Biosciences) in a 24-well plate at 1 × 10
5
 cells/mL. After 48 hours, cells on the 
lower side of the membrane were fixed with 4% paraformaldehyde and stained using a Diff Quick 
Staining Kit (Sysmex, Kobe, Japan). Stained cells were counted. Invading cells were standardized by 
migrating cells. 
 
Cell proliferation assay 
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shRNA-transfected neuroblastoma cells were seeded in 96-well plates at a density of 5 × 10
3
 cells 
per well in a final volume of 100 µL. The absorbance of each well was measured using a Dynatech 
MR5000 plate reader with a test wavelength of 450 nm and a reference wavelength of 630 nm. WST 
assay was performed according to the manufacturer’s instructions (Cell Counting Kit-8; Dojindo, 
Kumamoto, Japan). 
 
Sphere formation assay 
We evaluated neurospheres derived from BE (2)-C cells transfected with the indicated shRNA. We 
plated cells at 5 × 10
4
 cells/mL in 60-mm dishes to check the sphere morphology, and used a 96-well 
plate to count the spheres. The cells were allowed to proliferate in serum-free DMEM (Sigma) and 
F12 medium (Invitrogen) containing epidermal growth factor (Sigma) and 20 ng/mL basic fibroblast 
growth factor (Invitrogen) with 2% B27 supplement (Invitrogen). After 72 hours, colonies with 
diameters >100 µm were counted. 
 
Immunofluorescence analysis 
BE (2)-C and SK-N-AS cells were grown on coverslips and transfected with indicated shRNAs. 
Cells were fixed in 4% paraformaldehyde for 15 min at room temperature, blocked in 3% bovine 
serum albumin, stained with the indicated antibodies, and examined with a laser scanning confocal 
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microscope (DMI 4000B; Leica, Wetzlar, Germany). 
 
Asymmetric cell division (ACD) assay 
We tested whether neuroblastoma cells showed asymmetric distribution of NuMA. Asymmetric 
distributions of NuMA to one side of the cell were counted during mitotic stages. The spindle 
apparatus were also stained with anti-tubulin-α antibody to avoid false results caused by uneven 
dyeing. The antibodies used were as follows: anti-NuMA (Novus Biologicals, Littleton, CO, USA), 
and anti-tubulin-α (Thermo Fisher Scientific, Wilmington, DE, USA). 
 
Statistical analysis 
All data were presented as the mean ± standard deviation and were obtained from three independent 
experiments. Statistical significances in the clinical data were calculated using the log-rank test, 
Chi-square test, and Student’s t-test. Hazard ratios were calculated using univariate and multivariate 
Cox regression analysis. Statistical analyses were performed with JMP
®
 9 (SAS Institute Japan, 
Tokyo, Japan). Statistical significance was set at P < 0.05. 
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Figure & Table 
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Table 1. Prognostic significance of OCT4 expression and other clinical factors in MYCN-amplified neuroblastomas 
(Chi-square test). 
Factor 
OCT4 expression 
P-value 
Low (n = 22) High (n = 14) 
Age (month) 
<18 (n = 22) 11 11 
0.079 
≧18 (n = 14) 11 3 
INSS stage (3 or 4) 
3 (n = 9) 8 1 
<0.05 
4 (n = 27) 14 13 
Tumor origin 
Adrenal gland (n = 32) 19 13 
0.534 
Others (n = 4) 3 1 
Shimada classification 
Favorable (n = 6) 6 0 
<0.001 
Unfavorable (n = 30) 16 14 
MYCN expression 
Low (n = 25) 18 7 
<0.05 
High (n = 11) 4 7 
NCYM expression 
Low (n = 26) 21 5 
<0.001 
High (n = 10) 1 9 
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Figure Legends 
Figure 1. High OCT4 expression correlates with unfavorable prognosis in human MYCN-amplified 
neuroblastomas. (A) Overall survival of MYCN-amplified neuroblastomas according to relative 
OCT4 expression levels (n = 36; high, n = 14; low, n = 22). P-value by log-rank test. (B) Overall 
survival of MYCN-non-amplified neuroblastomas according to relative OCT4 expression levels (n = 
67; high, n = 22; low, n = 45). P-value by log-rank test. 
 
Table 1. Prognostic significance of OCT4 expression and other clinical factors in MYCN-amplified 
neuroblastomas (Chi-square test). 
 
Figure 2. NCYM regulates OCT4 via the recruitment of MYCN onto OCT4 promoter region in 
neuroblastoma cells. (A) Quantitative real-time RT-PCR analyses of NCYM, MYCN and OCT4 in 
NCYM shRNA-transfected BE (2)-C neuroblastoma cells. Three days after infection, mRNA 
expression levels were measured by real-time RT-PCR with β-actin as an internal control. (B) 
Western blot analyses of NCYM, MYCN, and OCT4 proteins in NCYM shRNA-transfected BE 
(2)-C neuroblastoma cells. Three days after infection, cells were subjected to western blot analyses. 
ACTIN was used as loading control. (C) Luciferase activity of MYCN and OCT4 reporters in NCYM 
shRNA-transfected BE (2)-C neuroblastoma cells. Seventy-two hours after infection, cells were 
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subjected to luciferase reporter assay. Data are shown as the fold change in the luciferase activity. 
The activities were standardized by control cells. (D) Schematic depiction of the OCT4 promoter 
region. The OCT4 promoter is divided into three regions (distal enhancer, distal promoter, and 
proximal promoter). Each conserved region (CR1-4) and translated region is boxed. The gray, white, 
and black boxes indicate the conserved region, non-coding region, and coding region, respectively. 
The locations of the chromatin immunoprecipitation (ChIP) primers are indicated by the bold lines. 
The putative E-box sites are shown in red boxes. (E) Identification of the MYCN binding region in 
the OCT4 promoter by ChIP assays. BE (2)-C neuroblastoma cells were transfected with or without 
shRNA. Three days after infection, cells were subjected to ChIP assay. Genomic DNA was amplified 
by PCR by specific primer sets as shown by bold black lines #1 and #2 in panel D. PCR bands 
indicated in panel #1 indicated amplification of the distal enhancer region; PCR bands indicated in 
panel #2 indicate amplification of the proximal enhancer region. 
 
Figure 3. OCT4 induced transcription of MYCN in neuroblastoma cells. (A) Quantitative real-time 
RT-PCR analysis of NCYM, MYCN and OCT4 in OCT4 shRNA-transfected BE (2)-C neuroblastoma 
cells. Seventy-two hours after infection, mRNA expression levels were measured by real-time 
RT-PCR with β-actin as an internal control. (B) Western blot analyses of NCYM, MYCN and OCT4 
proteins in OCT4 shRNA-transfected BE (2)-C neuroblastoma cells. Three days after infection, cells 
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were subjected to western blot analyses. ACTIN was used as loading control. (C) Luciferase activity 
of OCT4, NCYM and MYCN reporters after OCT4 shRNA-transfected BE (2)-C neuroblastoma cells. 
Seventy-two hours after infection, cells were subjected to luciferase reporter assay. Data are shown 
as the fold change in the luciferase activity. The activities were standardized by control cells. (D) 
Luciferase activity of MYCN (−221/+1312, −1030/+21 and −221/+465) reporters after OCT4 
transfection of SK-N-AS neuroblastoma cells. Forty-eight hours after transfection, cells were 
subjected to luciferase reporter assay. Data are shown as the fold change in the luciferase activity. 
The activities were standardized by control cells. (E) Luciferase activity of MYCN reporters 
(−221/+409, −221/+409 mutant 1, −221/+409 mutant 2, −221/+210 mutant and −221/+409 mutant) 
after OCT4 transfection of SK-N-AS neuroblastoma cells. Two days after transfection, cells were 
subjected to luciferase reporter assay. Data are shown as the fold change in the luciferase activity. 
The activities were standardized by control cells. The putative OCT4 binding sites are indicated in 
red boxes. Statistical significance determined by the Student’s t-test, *P < 0.05. (F) Schematic of the 
MYCN/NCYM promoter and coding region. These are divided into three exons (exon 1–3). Each 
translated region is boxed. The red and black boxes indicate the NCYM and MYCN regions, 
respectively. The locations of the chromatin immunoprecipitation (ChIP) primers are indicated by 
the bold line. The putative OCT4 binding sites are indicated by red boxes. (G) Identification of the 
OCT4 binding region in the MYCN/NCYM region by ChIP assays in BE (2)-C neuroblastoma cells. 
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Three days after infection, cells were subjected to ChIP assay. Genomic DNA was amplified by PCR 
using the primer sets shown in panel F. 
 
Figure 4. All-trans retinoic acid-induced neuronal differentiation abrogated the positive 
auto-regulatory loops formed by OCT4, MYCN, and NCYM. (A) Quantitative real-time RT-PCR 
analysis of NCYM, MYCN and ES cell-related genes in ATRA-treated BE (2)-C neuroblastoma cells. 
mRNA expression levels were measured by real-time RT-PCR with β-actin as an internal control. 
(B) Western blot analyses of NCYM, MYCN and OCT4 proteins in ATRA-treated BE (2)-C 
neuroblastoma cells. ACTIN was used as loading control. (C) Morphology of BE (2)-C 
neuroblastoma cells treated with or without ATRA. (D) Percentage of BE (2)-C neuroblastoma cells 
with marked neurite extensions relative to control with or without ATRA treatment. Error bars 
represent SEM from three independent experiments. (E) Identification of the MYCN-binding region 
in the OCT4 promoter by ChIP assays. BE (2)-C neuroblastoma cells were treated with or without 
ATRA. Genomic DNA was amplified by PCR using the primer sets shown in Figure 2D. (F) 
Identification of the OCT4 binding region in the MYCN/NCYM promoter by ChIP assays. BE (2)-C 
neuroblastoma cells were treated with or without ATRA. Genomic DNA was amplified by PCR 
using the primer sets shown in Figure 3F. 
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Figure 5. NCYM and OCT4 control cancer stem cell-like properties in neuroblastoma cells. (A) Cell 
viability assay of BE (2)-C neuroblastoma cells with NCYM or OCT4 shRNA-mediated knockdown. 
Cell proliferation was examined by WST assays at the indicated time points. (B) Sphere formation 
assay of BE (2)-C neuroblastoma cells. Representative images showing induction of sphere-forming 
activity after knockdown of NCYM and OCT4. Scale bars, 100 µm. (C) Quantification of sphere 
numbers from panel B. The numbers of spheres were counted 72 hours after infection. Error bars 
represent SEM from three independent experiments. (D) Invasion assay of BE (2)-C neuroblastoma 
cells. Representative images of showing invasion activity after knockdown of NCYM and OCT4. 
Scale bars, 100 µm. (E) Quantification of BE (2)-C neuroblastoma cells invading the Matrigel 
relative to control migration after NCYM and OCT4 shRNA-mediated knockdown from panel D. 
The numbers of spheres were counted 48 hours after infection. Error bars represent SEM from three 
independent experiments. (F) Representative images of symmetric distribution of NuMA during the 
late stage of mitosis in shRNA-treated neuroblastoma cells. Tubulin-α is indicated in red, NuMA is 
green and DNA is blue. Arrows show the distribution of NuMA on the cell cortex. Scale bars, 5 µm. 
(G) Quantification of cells with ACD in shRNA-transfected human neuroblastoma cells during late 
metaphase and anaphase. Error bars represent SEM from three experiments. Statistical significance 
determined by the Student’s t-test, *P < 0.05. 
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Table S1. Univariate Cox regression analysis using OCT4 expression level and clinical prognosis factors in MYCN-amplified 
neuroblastomas. 
Factor P-value HR (95% CI) 
Age (<18 vs. ≧18) 0.275 0.606 (0.249-1.512) 
INSS stage (4 vs. 3) 0.445 1.508 (0.551-5.277) 
Tumor origin (Adrenal gland vs. Others) 0.85 0.864 (0.241-5.507) 
Shimada classification (Unfavorable vs. Favorable) 0.775 1.191 (0.398-5.113) 
OCT4 expression (High vs. Low) 0.057 2.35 (0.971-5.838) 
MYCN expression (High vs. Low) 0.516 1.351 (0.527-3.279) 
NCYM expression (High vs. Low) 0.121 2.086 (0.813-5.074) 
 43 
 
Table S2. Multivariate Cox regression analysis using OCT4 expression level and clinical prognosis factors in 
MYCN-amplified neuroblastomas. 
Model Factor P-value HR (95% CI) 
A 
OCT4 expression (High vs. Low) <0.05 3.498 (1.307-9.837) 
Age (<18 vs. ≧18) 0.051 0.363 (0.13-1.005) 
B 
OCT4 expression (High vs. Low) 0.082 2.385 (0.896-6.919) 
INSS stage (4 vs. 3) 0.952 0.962 (0.285-3.746) 
C 
OCT4 expression (High vs. Low) <0.05 2.476 (1.002-6.338) 
Tumor origin (Adrenal gland vs. Others) 0.582 0.637 (0.166-4.174) 
D 
OCT4 expression (High vs. Low) 0.053 2.595 (0.986-7.542) 
Shimada classification (Unfavorable vs. Favorable) 0.645 1.394 (0.293-5.302) 
E 
OCT4 expression (High vs. Low) 0.072 2.466 (0.919-6.711) 
MYCN expression (High vs. Low) 0.829 0.894 (0.314-2.427) 
F 
OCT4 expression (High vs. Low) 0.256 2.083 (0.565-6.694) 
NCYM expression (High vs. Low) 0.769 1.203 (0.359-4.543) 
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Table S3. Multiple regression analysis for factors associated with OCT4 expression in neuroblastomas. 
 
  
Factor Standardised partial regression coefficient P-value 
Age 0.119 0.234 
Tumor origin 0.051 0.558 
INSS stage 0.036 0.711 
Shimada classification -0.09 0.372 
MYCN amplification -0.261 <0.05 
TRKA expression 0.026 0.783 
Ploidy -0.007 0.935 
NCYM expression 0.471 <0.05 
MYCN expression -0.104 0.467 
NANOG expression 0.422 <0.001 
SOX2 expression 0.1 0.314 
KLF4 expression -0.248 <0.05 
c-MYC expression 0.244 <0.05 
Constant 
 
0.935 
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Table S4. The correlation between NCYM and MYCN mRNA expression and embryonic stem cell-related genes in neuroblastomas. 
mRNA expression 
NCYM mRNA expression MYCN mRNA expression 
High NCYM 
(n=48) 
Low NCYM 
(n=45) 
P-value 
High MYCN 
(n=48) 
Low MYCN 
(n=45) 
P-value 
OCT4 mRNA expression 
High OCT4 
(n=46) 
33 13 
<0.001 
28 18 
0.075 
Low OCT4 
(n=47) 
15 32 20 27 
c-MYC mRNA expression 
High c-MYC 
(n=46) 
22 24 
0.303 
22 24 
0.303 
Low c-MYC 
(n=47) 
26 21 26 21 
KLF4 mRNA expression 
High KLF4 
(n=46) 
18 28 
<0.05 
17 29 
<0.01 
Low KLF4 
(n=47) 
30 17 31 16 
NANOG mRNA expression 
High NANOG 
(n=46) 
29 17 
<0.05 
27 19 
0.126 
Low NANOG 
(n=47) 
19 28 21 26 
SOX2 mRNA expression 
High SOX2 
(n=46) 
20 26 
0.089 
20 26 
0.089 
Low SOX2 
(n=47) 
28 19 28 19 
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Figure S1. NCYM and MYCN induced expression of embryonic stem cell-related genes 
Quantitative real-time RT-PCR analyses of NCYM, MYCN and ES cell-related genes in NCYM- or 
MYCN-transfected SK-N-AS neuroblastoma cells. Two days after transfection, mRNA expression 
levels were measured by real-time RT-PCR with β-actin as an internal control. Triangles indicate the 
increasing amount of NCYM expression plasmid (0, 50, 100 and 200 ng). 
 
Figure S2. Overexpression of c-MYC did not enhance the expression of OCT4, NCYM and MYCN in 
SK-N-AS human neuroblastoma cells Quantitative real-time RT-PCR analyses of NCYM, MYCN and 
OCT4 in c-MYC-transfected SK-N-AS neuroblastoma cells. Forty-eight hours after transfection, 
mRNA expression levels were measured by real-time RT-PCR with β-actin as an internal control. 
Triangles indicate the increasing amount of c-MYC expression plasmid (0, 50, 100 and 200 ng). 
 
Figure S3. NCYM and MYCN did not induce mouse Oct4 in mouse neuroblastoma cells (A) 
Quantitative real-time RT-PCR analysis of NCYM, MYCN and ES cell-related genes in 
NCYM-transfected Neuro2a mouse neuroblastoma cells. Forty-eight hours after transfection, mRNA 
expression levels were measured by real-time RT-PCR with β-actin as an internal control. Triangles 
indicate the increasing amount of NCYM expression plasmid (0, 50, 100 and 200 ng). (B) 
Quantitative real-time RT-PCR analysis of NCYM, MYCN and ES cell-related genes in 
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MYCN-transfected Neuro2a mouse neuroblastoma cells. Forty-eight hours after transfection, mRNA 
expression levels were measured by real-time RT-PCR with β-actin as an internal control. Triangles 
indicate the increasing amount of MYCN expression plasmid (0, 50, 100 and 200 ng). 
 
Figure S4. The expression of OCT4 mRNA in tumors developed from MYCN and MYCN/NCYM Tg 
mice. Quantitative real-time RT-PCR analyses of OCT4 in tumors of MYCN and MYCN/ NCYM Tg 
mice. mRNA expression levels were measured by real-time RT-PCR with GAPDH as an internal 
control. 
 
Figure S5. Conservations of OCT4 binding and E-box site in OCT4 promoter and MYCN/NCYM 
regions. (A) Sequences of putative E-box sites in the OCT4 promoter in human and other species. 
Sequences were extracted from the UCSC genome browser on the basis of conservation. Red text 
indicates sequence differences compared with the human sequence. The putative E-box sites are 
indicated by the bold line. (B) Sequences of putative OCT4-binding sites in the MYCN/NCYM region 
in human and other species. Sequences were extracted from the UCSC genome browser on the basis 
of conservation. Red text indicates sequence differences compared with the human sequence. The 
putative OCT4-binding site is indicated by the bold line. 
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Figure S6. OCT4 induces the expression of NCYM and MYCN in neuroblastoma cells. (A) 
Quantitative real-time RT-PCR analysis of NCYM and MYCN in OCT4-transfected SK-N-AS 
neuroblastoma cells. Forty-eight hours after transfection, mRNA expression levels were measured by 
real-time RT-PCR with β-actin as an internal control. (B) Luciferase activity of MYCN and NCYM 
reporters after OCT4 transfection of SK-N-AS neuroblastoma cells. Forty-eight hours after 
transfection, cells were subjected to luciferase reporter assay. Data are shown as the fold change in 
the luciferase activity. The activities were standardized by control cells. 
 
Figure S7. Asymmetric cell division in human neuroblastoma cells. (A) Representative images of 
symmetric distribution of NuMA during the late stage of mitosis in SK-N-AS 
(MYCN-non-amplified) and BE (2)-C (MYCN-amplified) neuroblastoma cells. Tubulin-α is indicated 
in red, NuMA is green and DNA is blue. Arrows show the distribution of NuMA on the cell cortex. 
Scale bars, 5 µm. (B) Quantification of cells with ACD in human neuroblastoma cells during late 
metaphase and anaphase. Error bars represent SEM from three independent experiments. Statistical 
significance determined by the Student’s t-test, *P < 0.05. 
 
Figure S8. Conservations of the E-box site at the MYCN/NCYM region. (A) Sequences of putative 
E-box sites in the MYCN/NCYM region in human and other species. Sequences were extracted from 
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the UCSC genome browser on the basis of conservation. Red text indicates sequence differences 
compared with the human sequence. The putative E-box sites are indicated by the bold line. 
 
Table S1. Univariate Cox regression analysis using OCT4 expression level and clinical prognosis 
factors in MYCN-amplified neuroblastomas. 
 
Table S2. Multivariate Cox regression analysis using OCT4 expression level and clinical prognosis 
factors in MYCN-amplified neuroblastomas. 
 
Table S3. Multiple regression analysis for the factors associated with OCT4 expression 
neuroblastomas. 
 
Table S4. The correlation between NCYM, MYCN mRNA expression and ES cell-related genes in 
neuroblastoma 
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